Morphotek Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
10/28/2009 7:00:42 AM
More...
|
Morphotek Inc.: Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
9/24/2009 8:55:36 AM
More...
|
Morphotek Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
9/23/2009 11:38:23 AM
More...
|
Morphotek Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
7/15/2009 9:56:32 AM
More...
|
Morphotek Inc. Announces a Research Collaboration Agreement with Synageva BioPharma to Develop Potential Treatments for Cancer and Infectious Disease
7/1/2009 7:16:00 AM
More...
|
Morphotek Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors
6/9/2009 10:02:51 AM
More...
|
Morphotek Inc. and Lonza Group Ltd. Enter Into Manufacturing Services Agreement
5/19/2009 11:25:07 AM
More...
|
Human Genome Sciences, Inc. (HGSI) and Morphotek Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3/25/2009 7:28:13 AM
More...
|
Morphotek Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
3/23/2009 7:29:44 AM
More...
|
Morphotek Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
3/2/2009 10:23:07 AM
More...
|
|